U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06838949) titled 'A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP' on Jan. 21.
Brief Summary: The objective of this study was to evaluate the efficacy and safety of Herombopag in the treatment of elderly patients with ITP.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Herombopag
Intervention:
DRUG: herombopag olamine tablets
The patient received herombopag 5mg/d at the beginning of the day, was orally taken on an empty stomach in the morning, and could eat 2 hours after taking the drug, once a day for 24 weeks. Investigators will adjust the dosage of herombopag once a week a...